AbbVie completes acquisition of Aliada Therapeutics to enhance neuroscience development
12/11/24, 3:06 PM
Location
north chicagobostonIndustry
biotechnology
AbbVie completed the acquisition of Aliada Therapeutics, a company focused on the development of therapeutic solutions for Alzheimer's disease. With this acquisition, AbbVie aims to advance potentially disease-modifying therapies such as ALIA-1758 for Alzheimer's disease and bolster their neuroscience discovery and development efforts by leveraging Aliada's novel CNS drug delivery platform.
Company Info
Location
North Chicago, Illinois, United States
Company info
Cerevel Therapeutics is a biopharmaceutical company dedicated to developing therapies for neuroscience. It focuses on curing diseases associated with the central nervous system, specializing in treating disorders such as schizophrenia and epilepsy. Cerevel is known for its innovative approaches to complex neurological conditions. The company went public and was listed on NASDAQ under the ticker symbol CERE.